Griffith University researchers may have unlocked the secret to treating sepsis, with a Phase II clinical trial in China successfully concluding with promising results.

Press release from Griffith University:

Griffith University researchers may have unlocked the secret to treating sepsis, with a Phase II clinical trial in China successfully concluding with promising results.

The sepsis drug candidate, a carbohydrate-based drug called STC3141, was co-developed by Distinguished Professor Mark von Itzstein AO FAA FAHMS FRACI AO and his team from Griffith University Institute for Biomedicine and Glycomics, and Professor Christopher Parish and his team at The Australian National University.

“The trial met the key endpoints to indicate the drug candidate was successful in reducing sepsis in humans,” Professor von Itzstein said.

The small-molecule experimental drug was a carbohydrate-based molecule and could treat sepsis by reversing organ damage.

“When sepsis is not recognised early and managed promptly, it can lead to septic shock, multiple organ failure and death,” Distinguished Professor von Itzstein said.

The trial, conducted by Grand Pharmaceutical Group Limited (Grand Pharma), involved 180 patients with sepsis, one of the leading causes of death and long-term disability worldwide.

Currently, there is no specific anti-sepsis therapy available, and sepsis is considered a clinical unmet need.

Professor von Itzstein said Grand Pharma would now look to progress to a Phase III trial to continue testing the efficacy of the novel treatment.

“It’s hoped we could see the treatment reach the market in a handful years, potentially saving millions of lives,” he said.

Griffith University:

griffith.edu.au

Australian National University:

anu.edu.au

Professor Mark von Itzstein:

experts.griffith.edu.au/18853-mark-von-itzstein

Professor Mark von Itzstein AO was the founding Director of Griffith University’s Institute for Glycomics in 2000. He has a major research effort in the area of drug discovery, with a carbohydrate-based drug candidate against sepsis in phase 2 human clinical trials. Professor von Itzstein led the team responsible for the design, synthesis and biological evaluation of the anti-influenza drug, Relenza®, which has been approved for the treatment of influenza worldwide since 1999. This discovery is considered to be a significant outcome and flagship in glycotherapeutic and antiviral drug development in the last century.

Photo: © Griffith University

All rights belong to: (for this news)

Griffith University - Griffith University Institute for Biomedicine and Glycomics

Australian National University

Professor Mark von Itzstein AO FAA FAHMS FRACI AO

Projekt owner & Team on Projekt

At ESCCongress 2026, your cardiovascular community gathers to exchange ideas, learn from leading experts, and transform patient care.

Media release from European Society of Cardiology:

The world’s foremost cardiology congress is coming to Munich.

At ESCCongress 2026, your cardiovascular community gathers to exchange ideas, learn from leading experts, and transform patient care.

Across four days, you will experience:

• Direct access to global leaders

• Hands-on sessions and immersive learning experiences

• Dialogue across every cardiovascular subspecialty

• New connections that spark collaboration and progress

Explore the Scientific Programme, register before 31 May to save and join your peers in Munich.

28–31 August 2026 | Munich, Germany

Registration: escardio.org/esc-congress/registration/

Photo: © ESC (Corrected!)

All rights belong to: (for this news)

European Society of Cardiology

Prof. Dr. Jan Halbritter has served as the new Medical Director of the Department of Medicine IV – Nephrology at the Medical Center – University of Freiburg since April 2026.

Focus on Genetic Kidney Diseases / Plans to Expand Clinical Trials

Prof. Dr. Jan Halbritter has served as the new Medical Director of the Department of Medicine IV – Nephrology at the Medical Center – University of Freiburg since April 2026. With his clinical and scientific expertise, he is enhancing care for patients with kidney disease: The primary goal is to prevent kidney failure through targeted early diagnosis and the implementation of innovative strategies to slow disease progression. For cases where kidney failure has already occurred, the focus is on organ replacement, particularly through the advancement of transplant medicine. Halbritter succeeds Prof. Dr. Gerd Walz, who has led the department since 1999 and developed it into one of the nation’s leading centers for nephrology.

The kidneys perform vital functions in the body, such as filtering waste products, regulating water and electrolyte balance, and producing hormones. In Germany, approximately two million people are affected by kidney disease, often requiring dialysis and, in some cases, an organ transplant.

Gaining a Better Understanding of Hereditary Kidney Diseases

In addition to acquired causes such as diabetes or high blood pressure, genetic factors play a key role. Halbritter’s scientific focus is on nephrogenetics: The precise characterization of the clinical and molecular profiles of genetically determined kidney diseases such as polycystic kidney disease, glomerulopathies, and hereditary kidney stone disorders is intended to help identify disease causes early, better understand them, and find new therapeutic approaches.

“Freiburg is a nationally and internationally renowned center for renal genetics,” says Halbritter. “I want to leverage and further develop the existing excellent infrastructure so that patients can benefit from new diagnostic and therapeutic options at an early stage.”

Halbritter (47) studied medicine in Bonn, Cologne, and Lyon. He completed his residency at Leipzig University Hospital, supplemented by research stays in the U.S. (Ann Arbor, Boston). Most recently, he headed the Center for Rare Kidney Diseases (CeRKiD) at Charité – Universitätsmedizin Berlin and held a Heisenberg Professorship in Genetic Kidney Diseases.

Further information: uniklinik-freiburg.de/en/new-medical-director

Photo: © Medical Center – University of Freiburg

All rights belong to: (for this news)

Universitätsklinikum Freiburg

LIVESTREAM: Preliminary press conference for the 130th German Medical Assembly 2026

With the law to stabilize statutory health insurance contributions, Germany is facing one of the most extensive cost-cutting programs for statutory health insurance in decades. At the same time, the planned introduction of primary care, the reorganization of emergency care, and the practical implementation of hospital reform in the federal states will bring about profound structural changes in the healthcare system.

What impact will the reforms have on healthcare? How will the working conditions of employees in our healthcare system change? How can healthcare structures be designed to be sustainable for the future? The 130th German Medical Assembly, taking place in Hanover from May 12 to 15, 2026, will address these and other current healthcare policy issues.

Live stream at: bundesaerztekammer.de/pressekonferenzen

Photo: © SFK - Archive

All rights belong to: (for this news)

Bundesärztekammer

The president of the German Medical Association, Dr. Klaus Reinhardt, is demanding at least three billion euros from the federal government as a first step towards the full refinancing of non-insurance-related services in the statutory health insurance system:

“Stabilizing health insurance finances is a major undertaking for society as a whole. Therefore, it is absolutely unacceptable that the Federal Finance Minister is literally shirking his responsibility while healthcare workers, insured individuals, and patients are expected to bear the brunt of the planned statutory health insurance savings package.

So far, Minister Klingbeil has shown no willingness whatsoever to even begin the process of fully refinancing non-insurance-related services with federal funds. A first, urgently needed step would be an additional tax subsidy to the health fund of at least three billion euros, which must be consistently expanded in the coming years.

The Federal Government's Finance Commission on Health has also explicitly recommended that non-insurance-related services be fully financed through the federal budget. According to their calculations, the annual requirement is approximately €12.5 billion. This funding gap must not be closed by cutting benefits or by imposing additional burdens on insured individuals, patients, or healthcare workers.

In this context, I recommend that the Federal Minister of Finance also follow the proposals of the Finance Commission on Health on another point. The Commission suggests introducing or increasing taxes on harmful indulgences such as spirits, tobacco, and sugary drinks, and allocating the resulting revenue specifically to the healthcare system. This would not only finance the first step towards the full refinancing of non-insurance-related services, but also create the necessary framework for effective preventive measures.

Instead, the federal government is currently only planning to raise the tobacco tax – and even then, only to offset the announced tax-free relief bonus for employees. Therefore, there is no question of a consistent, politically sound overall strategy.

Furthermore, higher taxes or levies on harmful substances also have a preventive effect. Higher prices can demonstrably reduce consumption and, in particular, raise the barriers to entry for children and young people. They are therefore an important component in the fight against the major widespread diseases of our time, such as cancer, heart disease, COPD, and obesity.

If real progress were finally made here, it would not only have a positive impact on the health of every individual, but would also relieve the economy of billions in the long term".

Press release from German Medical Association: 22.04.2026

bundesaerztekammer.de/presse

Photo: ©BÄK (Corrected!)

All rights belong to: (for this news)

Bundesärztekammer - Dr. Klaus Reinhardt

Federal Health Minister Nina Warken will also come to Hanover for the opening of the 130th German Medical Assembly on May 12th.

Media release from German Medical Association:

The 130th German Medical Assembly will take place in Hanover from May 12th to 15th, 2026.

We are very pleased that Federal Health Minister Nina Warken has agreed to accompany us to Hanover on May 12th for the opening of the 130th German Medical Congress.

The 130th German Medical Assembly will address important health policy projects of the Federal Government, such as the introduction of a primary care system and the reform of the hospital landscape and emergency care.

A key focus of the German Medical Assembly's working sessions is the topic of addiction and drugs. Together with the Federal Government's Drug Commissioner, Prof. Dr. Hendrik Streeck, and other renowned speakers, the delegates of the Medical Assembly will discuss developments in addiction medicine, prevention, and the responsibility of physicians in dealing with addiction disorders.

More information about the 130th German Medical Assembly can be found at:

bundesaerztekammer.de/aerztetag/130-daet-2026-in-hannover

Photo: ©BÄK (HCC)

All rights belong to: (for this news)

Bundesärztekammer

Ahead of tomorrow's hearing on the draft bill for a statutory health insurance contribution rate stabilization law at the Federal Ministry of Health, the President of the German Medical Association, Dr. Klaus Reinhardt, stated:

"According to Chancellor Friedrich Merz, the statutory health insurance contribution rate stabilization law planned by the federal government is one of the biggest social welfare reforms in our country. In fact, we are facing one of the most extensive cost-cutting measures for statutory health insurance in decades, with potentially far-reaching consequences for patient care, for those insured, and for employees in our healthcare system.

The fact that those involved are given only four days over a weekend to review and evaluate a law exceeding 150 pages, containing such fundamental cuts and changes, is all the more unacceptable. These deadlines are a heavy-handed approach and completely inappropriate in this context. While there is every understanding of the urgent need for action, speed must not take precedence over thoroughness in such an important undertaking.

Despite this exceptionally tight deadline, we have conducted a detailed initial assessment of the draft and will clearly present our positions in the further parliamentary process. A particularly egregious example is the omission of the full refinancing of health insurance contributions for recipients of basic income support from the draft. This demonstrates a lack of appreciation for the insured and those working in the healthcare sector, who must bear the burden of this solidarity measure through cost-cutting measures, fee reductions, and increased workloads. The complete assumption of these costs by the federal budget would not only be essential from a regulatory policy perspective, but would also reflect a properly understood concept of societal solidarity.

It is now crucial to have sufficient time to carefully analyze the consequences of all measures planned under the law for patient care and to assess their interactions with one another. This is also important in order to properly evaluate the impact of the law on ongoing or pending reform projects, such as the introduction of the primary care system, the reorganization of emergency care, and the implementation of hospital reform.

In the further parliamentary process, we will pay very close attention to whether those affected are honestly and seriously involved in the detailed design of the reform, or whether it becomes a mere parliamentary formality. The acceptance and support of the reform by the medical profession will depend significantly on this."

Media release from Bundesärztekammer: 19.04.2026 bundesaerztekammer.de/presse

Photo: ©BÄK (Corrected!)

All rights belong to: (for this news)

Bundesärztekammer - Dr. Klaus Reinhardt

Internationally Renowned Cancer and Stem Cell Researcher to Lead Bronx-Based NCI-Designated Center.

Media release from Albert Einstein College of Medicine:

We are proud to announce that Ulrich Steidl, M.D., Ph.D., an international leader in blood cancer and stem cell research, has been named director of the Montefiore Einstein Comprehensive Cancer Center (MECCC) and vice president of cancer medicine at Montefiore Health System.

Dr. Steidl has served as interim director since late 2025 and previously held multiple leadership roles within MECCC, a National Cancer Institute (NCI)-designated comprehensive cancer center. Since joining Montefiore Einstein in 2008, he has built a distinguished career advancing our understanding of pre-leukemic stem cells and developing innovative approaches to cancer prevention and treatment.

His pioneering research has helped shape the concept of “precision prevention” and contributed to therapies now in clinical trials. An inventor on numerous patents and a co-founder of successful biotech startups, Dr. Steidl is also a dedicated mentor and collaborator. He has received numerous honors, including awards from the National Cancer Institute, Blood Cancer United, the International Society for Experimental Hematology (ISEH), and the V Foundation for Cancer Research, and is an elected member of the Association of American Physicians and the American Society for Clinical Investigation.

“I am deeply honored to accept the leadership of MECCC,” said Dr. Steidl. “We have a tremendous team composed of exceptional clinicians, researchers, and administrators who are deeply dedicated to our patients, our community, and cutting-edge cancer care and innovative science. I look forward to working together as we advance our mission to reduce the burden of cancer in the Bronx and beyond, and drive innovation that improves the lives and well-being of people in our borough and around the world.”

To read more, visit: montefioreeinstein.org/ulrich-steidl

Albert Einstein College of Medicine: einsteinmed.edu

Montefiore Einstein: montefioreeinstein.org

Photo: ©Montefiore (Corrected!)

All rights belong to: (for this news)

Ulrich G. Steidl, M.D., Ph.D.

Albert Einstein College of Medicine

Montefiore Einstein

Dyspnea Symposium will take place at the Gottlieb Duttweiler Institute in Rüschlikon - an interdisciplinary exchange around the complex symptom dyspnea.

Media release from Universitätsspital Zürich:

On May 30, 2026, the Dyspnea Symposium will take place at the Gottlieb Duttweiler Institute in Rüschlikon - an interdisciplinary exchange around the complex symptom dyspnea.

Participants can expect a varied program with current scientific updates, practical workshops and exciting discussions. The focus is on the diverse causes of respiratory distress as well as their diagnostic and therapeutic approaches in everyday clinical practice.

The event is aimed at medical professionals and offers an ideal platform for knowledge transfer, networking and the exchange of information on current developments in pneumology.

More on our website: usz.ch/veranstaltung/dyspnoe-symposium-2026

Universitätsspital Zürich: usz.ch

LUNGE ZÜRICH: lunge-zuerich.ch

Photo: © USZ

All rights belong to: (for this news)

Universitätsspital Zürich - LUNGE ZÜRICH

Organization owner & Team on organizing

The 24th National Congress of Surgery was successfully held in Antalya.

Media release from Turkish Surgical Association:

The 24th National Congress of Surgery was successfully held in Antalya.

The congress, attended by former and current surgical directors, addressed the training of surgical assistants, the problems they face, and proposed solutions.

for more: uck2026.org/EN

TCD (Turkish Surgical Association): turkcer.org.tr

Photo: ©TCD

All rights belong to: (for this news)

TCD (Turkish Surgical Association)

24th National Congress of Surgery - Organization owner & Team on organizing

Participants were happy to come together on this meaningful day, which draws attention to the importance of professional solidarity and unity.

Media release from SANKO University: (Original text)

A meaningful celebration program was held on the occasion of April 8 Physiotherapists' Day in the organization of the Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation and Fizyolife Club. The event, which gained meaning with the participation of the Gaziantep Provincial Representative of the Turkish Physiotherapists Association (TFD), Specialist Physiotherapist Yakup Can Ayçin, and his valuable messages emphasizing the importance of the profession, attracted great attention.

Within the scope of the program, the place and importance of the physiotherapy profession in the field of health and its contributions to patient quality of life were discussed, and inspiring shares were made that increased professional motivation for students. Participants were happy to come together on this meaningful day, which draws attention to the importance of professional solidarity and unity.

To the event; Our Rector Prof. Dr. Güner Dağlı, our Secretary General Dr. Yusuf Ziya Yıldırım and our Dean of the Faculty of Medicine Prof. Dr. Salih Murat Akkın also attended.

SANKO University: sanko.edu.tr/en

Photo: ©SANKO

“All rights belong to SANKO Üniversitesi” (for this news)

The 1st Halle Symposium for Emergency Medicine will create a new platform for interdisciplinary exchange in emergency medicine.

Media release from Universitätsmedizin Halle:

With the 1st Halle Emergency Medicine Symposium (HaNSy), we aim to create a new platform for interdisciplinary exchange in emergency medicine.

Under the overarching theme of “Rescue service of the future”, the focus is on practical presentations and a panel discussion with representatives from hospitals, emergency services, professional associations and air rescue.

The report sheds light on current and controversial topics as well as structural developments of the coming years.

Together with experts from different healthcare sectors, challenges are analyzed, opportunities are identified, and concrete solutions for the future of emergency care are discussed.

May 12, 2026

for more: hallenser-notfallmedizin-symposium-hansy

Organizer: University Clinic for Anesthesiology and Surgical Intensive Care

Universitätsmedizin Halle: umh.de

Medizinischen Fakultät der Martin-Luther-Universität Halle-Wittenberg: medfak.uni-halle.de

Medizinischen Fakultät Halle: umh.de/medizinische-fakultaet

Photo: ©Universitätsmedizin Halle

All rights belong to: (for this news)

Universitätsmedizin Halle - 1. Hallenser Notfallmedizin-Symposium (HaNSy)

Universitätsklinik für Anästhesiologie und Operative Intensivmedizin

Deutsche Akademie der Naturforscher Leopoldina e. V

The KBGGG/SRMBL - Forensic Scientific Afternoon 2026 is a scientific event intended for professionals active in forensic medical, judicial, and forensic sciences.

Media release from Royal Belgian Society of Legal Medicine (SRMLB-KBGGG):

Forensic Scientific Afternoon & Gala Cocktail Dinner 2026

The KBGGG/SRMBL - Forensic Scientific Afternoon 2026 is a scientific event intended for professionals active in forensic medical, judicial, and forensic sciences.

This annual meeting aims to promote sharing knowledge, interdisciplinary dialogue, and professional exchange in a context where scientific, legal, and ethical challenges are rapidly evolving.

This event is organized by the Royal Belgian Society of Legal Medicine (KBGGG/SRMLB) and combines a scientific afternoon session with a networking walking dinner, bringing together Belgian and international experts.

The presentations will take place in English.

Registration is now open for the KBGGG / SRMLB Forensic Scientific Afternoon & Gala Dinner 2026!

The Royal Belgian Society of Legal Medicine (KBGGG / SRMLB) is pleased to welcome professionals, researchers, and students to this key annual scientific event.

We warmly encourage participants to submit an abstract for a 10-minute oral presentation and actively contribute to a dynamic and high-level scientific exchange.

Deadline for abstract submission: April 16.

Submit your abstract here: kbgggsrmlb.odoo.com/abstract

Find more information and register here: forensic-scientific-afternoon-2026-1/register

Registration via the LinkedIn event alone is not sufficient — please complete your official registration through the link above.

We look forward to welcoming you in Brussels.

Royal Belgian Society of Legal Medicine (SRMLB-KBGGG): kbgggsrmlb.odoo.com

Dr. Jessica Vanhaebost, President of the Royal Belgian Society of Legal Medicine (SRMLB-KBGGG) said:

"I’m very happy to open registrations for the SRMLB/KBGGG Forensic Scientific Afternoon & Standing Dinner 2026. This will be my first scientific meeting organized as President of the Royal Belgian Society of Legal Medicine, and I truly hope to see many colleagues and friends from the forensic community there. We warmly encourage abstract submissions for 10-minute oral presentations. Looking forward to an inspiring afternoon of forensic science and discussions in Brussels".

Photo: © SRMLB-KBGGG

“All rights belong to Royal Belgian Society of Legal Medicine (SRMLB-KBGGG)” (for this news)

The "Age Well Neighbourhoods" initiative is a significant step toward plugging gaps in senior services, starting with Toa Payoh.

Media release from Duke-NUS Medical School:

As Singapore prepares for a future where one in four citizens will be aged 65 or above by 2030, Assoc Prof Rahul Malhotra and Dr Jeremy Lim-Soh from the Duke-NUS Centre for Ageing Research and Education are looking at how neighbourhoods can better support ageing-in-place.

The "Age Well Neighbourhoods" initiative is a significant step toward plugging gaps in senior services, starting with Toa Payoh. However, effective support goes beyond infrastructure—it requires a shift toward "person-centric" care that respects the unique routines and aspirations of our seniors.

By integrating place-centric policies with a deeper understanding of individual needs, we can create communities where seniors don't just live, but truly thrive with dignity and purpose.

Read more about it from the link: age-well-neighbourhoods

Duke-NUS Medical School: duke-nus.edu.sg

Duke University School of Medicine: medschool.duke.edu

National University of Singapore (NUS): nus.edu.sg

Photo: ©Duke-NUS

“All rights belong to: (for this news)

Duke-NUS Medical School

Assoc Prof Rahul Malhotra

Dr Jeremy Lim-Soh - Duke-NUS Centre for Ageing Research and Education

Initiative "Age Well Neighbourhoods"

The scanner enables detailed analysis of individual cells within tumours, including those that may drive metastasis or express key markers that can inform more effective treatment strategies.

Media release from National Breast Cancer Research Institute:

New Scanner a ‘Game Changer’ for breast cancer research

The exceptional corporate partnership that was formed between the National Breast Cancer Research Institute (NBCRI) and Hewlett Packard Enterprise (HPE), supported by CÚRAM, Research Ireland Centre for Medical Devices and the University of Galway - College of Medicine, Nursing and Health Sciences, has enabled the installation of a cutting-edge multiplex imaging scanner at the Lambe Institute, part of University of Galway.

“This is a ‘Game Changer”, says Director of Research at NBCRI, Professor Michael Kerin. “The scanner enables detailed analysis of individual cells within tumours, including those that may drive metastasis or express key markers that can inform more effective treatment strategies. The purchase of this equipment is a tremendous example of the strength of collaboration, demonstrating how organisations and corporate partnerships such as HPE can make a truly life-changing difference for patients.”

The purchase of this machine, the first in the country, really shows what can be achieved when corporate partnerships, such as HPE and NBCRI develop and make a life changing difference for patients.

The National Breast Cancer Research Institute is a national charity that funds a comprehensive research programme at University of Galway.

Research has improved the diagnosis, treatment options, and outcomes for those who develop breast cancer. The charity funds these research programmes to continue to impact the outcomes for those who develop the disease.

National Breast Cancer Research Institute: NBCRI is a national charity funding a comprehensive breast cancer research programme at University of Galway.

Read the full press release here: new-scanner-a-game-changer-for-breast-cancer-research

To learn more about the scanner, Watch Here: youtu.be/gv2o3YJT5S0 (YouTube)

NBCRI: breastcancerresearch.ie

Media release from University of Galway - College of Medicine, Nursing and Health Sciences:

"A great example of what can be achieved when research, healthcare and industry come together to make a real impact. This new scanner will significantly advance breast cancer research and, ultimately, improve outcomes for patients".

University of Galway - College of Medicine, Nursing and Health Sciences:

medicine-nursing-and-health-sciences

Photo: ©NBCRI

Video: ©NBCRI

All rights belong to: (for this news)

University of Galway - College of Medicine, Nursing and Health Sciences

National Breast Cancer Research Institute (NBCRI)

Hewlett Packard Enterprise (HPE)

CÚRAM, Research Ireland Centre for Medical Devices

Lambe Institute for Translational Research & HRB Clinical Research Facility

The result speaks for itself: rapid recovery, functioning transplants, discharge after a few days – without complications.

Media release from Univ.-Prof. Dr. med. univ. MBA Robert Öllinger:

Four kidney transplants in seven days – robotically!

What was an exception just a few years ago is increasingly becoming reality in Vienna.

At the Clinical Department of Transplantation of the Medical University of Vienna / the University Hospital AKH, ​​four transplants were performed using the DaVinci system within one week: two after living donation, two after post-mortem organ donation.

The result speaks for itself: rapid recovery, functioning transplants, discharge after a few days – without complications.

The dedicated nursing team led by Natalie Libera and the surgical team led by Jakob Eichelter and Robert Öllinger have the most experience in the German-speaking world and are driving a development that has the potential to sustainably change transplant surgery.

The crucial question is no longer whether robotic transplantation will be performed – but how quickly this method will become more widely established.

Also live on April 24, 2026, during the Long Night of Research.

Link: langenachtderforschung.at

Rector of the Medical University of Vienna, Univ.-Prof. Dr. med. univ. Markus Müller says:

"Our new head of transplantation surgery „hits the ground running“ together with his great team Robert Öllinger Natalie Libera Jakob Eichelter".

MedUni Wien: meduniwien.ac.at/web

Photo: ©MedUni Wien

All rights belong to: (for this news)

Medizinische Universität Wien | Universitätsklinikum AKH Wien

Univ.-Prof. Dr. med. univ. Markus Müller | Univ.-Prof. Dr. med. univ. MBA Robert Öllinger

Pflegeteam unter der Leitung von Natalie Libera

OP-Team unter der Leitung von Jakob Eichelter und Robert Öllinger

Congratulations!

SFK Agency | News

The current PhD Call at MedUni Vienna offers a range of exciting opportunities in this field and many more projects in cardiovascular biology.

Media release from Medizinische Universität Wien:

Interested in cardiovascular biology?

The current PhD Call at MedUni Vienna offers a range of exciting opportunities in this field.

Join a research group and work on topics such as:

Elucidating the role of IgG antibodies in atherosclerosis (with Florentina Porsch & Christoph Binder)

Investigating how dyslipidemia affects hematopoiesis in the skull (with Máté Kiss)

…and many more projects in cardiovascular biology.

Become part of an international research environment, contribute to cutting-edge science, and take the next step in your academic career.

Find all projects and apply here: open-phd-positions

MedUni Wien: meduniwien.ac.at/web/

Photo: ©MedUni Wien

“All rights belong to Medizinische Universität Wien” (for this news)

The winner of the German Cancer Prize 2026 in the category “Health Services Research” is Professor Dr. med. Jochen Schmitt

Media release from Innovationsausschuss (IA):

German Cancer Prize 2026

The German Cancer Prize has been awarded annually since 1986 for outstanding work in German-speaking countries in the following categories:

-Experimental basic oncological research

-Translational research

-Tumor diagnostics and treatment

-Health services research

The winner of the German Cancer Prize 2026 in the category “Health Services Research” is Professor Dr. med. Jochen Schmitt from TU Dresden as head of the WiZen project funded by the Innovation Committee.

The WiZen project aims to assess the quality of care in certified organ cancer centers compared to non-certified hospitals. Based on (GKV) statutory health insurance billing data and cancer registry data, it has been shown that patients in certified centers have a survival advantage.

With his research, Prof. Dr. med. Schmitt demonstrates how healthcare research can directly improve practice:

- Through the development of new care models

- Methodological groundwork

- Testing of new evidence-based forms of care for patients

The results from WiZen provide important insights into the quality of cancer treatments in certified centers compared to other clinics and give patients guidance in choosing a clinic.

-The resulting insights are highly relevant for those affected, service providers, payers, health policy and society as a whole.

The Innovation Committee congratulates Professor Dr. med. Jochen Schmitt and the WiZen project team on their recognition and their crucial contribution to healthcare research in Germany.

Further information about the project can be found here:

innovationsfonds.g-ba.de/projekte/wizen

Innovationsausschuss (IA):

innovationsfonds.g-ba.de

Photo: ©Jochen Schmitt

All rights belong to: (for this news)

Innovationsausschuss (IA) | G - BA | WiZen project & team | Prof. Dr. med. Jochen Schmitt

The Prof. Dr. Suphi Artunkal Prize, considered the most prestigious award in nuclear medicine in Turkey, was awarded to Prof. Dr. Çiğdem Soydal and her team.

Media release from Medical Faculty of Ankara University:

Highest award in nuclear medicine for Prof. Dr. Çiğdem Soydal

The Medical Faculty of Ankara University has received another prestigious award. A multicenter study led by Prof. Dr. Çiğdem Soydal, a member of the Faculty of Nuclear Medicine, has been awarded the "Prof. Dr. Suphi Artunkal Award".

At the awards ceremony during the National Congress of Nuclear Medicine, the Prof. Dr. Suphi Artunkal Prize, considered the most prestigious award in the field of nuclear medicine in Turkey, was awarded this year to our faculty member Prof. Dr. Çiğdem Soydal and her team.

for more: medicine.ankara.edu.tr/2026/04/08/prof-dr-cigdem-soydal

Medical Faculty of Ankara University: medicine.ankara.edu.tr

Photo: © AÜ

“All rights belong to Medical Faculty of Ankara University” (for this news)

Media release from Helios Kliniken:

Biological aortic valves do not last indefinitely. If further intervention becomes necessary, the treatment decision requires a sound basis. This is precisely what the international REPEAT study is working on. This year's World Health Day focuses on strengthening science as the foundation for better health. This is also the aim of this study.

Helios participates in this through the Helios Health Institute. There, Helios consolidates clinical studies and health research. The institute supports research projects and works with healthcare data from everyday clinical practice to make medical findings applicable to patient care.

This is relevant for cardiology because the study addresses a specific question in patient care that has not yet been answered by a direct randomized controlled trial with long-term follow-up. The REPEAT trial aims to contribute to a more reliable data basis for future decisions regarding repeat interventions on biological aortic valves.

Prof. Dr. med. Michael A. Borger, PhD, Medical Director, Director of the University Clinic for Cardiac Surgery & Professor of Cardiac Surgery at the University of Leipzig, says:

"Our international collaboration shows how research can work across borders – and how we can jointly develop therapies that bring real long-term benefits to our patients"

for more: helios-gesundheit.de

Photo: ©Helios

“All rights belong to Helios Kliniken GmbH” (for this news)